Cap/Iri Plus Cetuximab Compared to Cap/ox Plus Cetuximab in Patients With Metastatic Colorectal Cancer.

Sponsor
Ludwig-Maximilians - University of Munich
Study ID
NCT00254137
Phase
PHASE2
Status
Completed

Conditions

  • Metastatic Colorectal Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

  • capecitabine — DRUG
  • irinotecan — DRUG
  • oxaliplatin — DRUG
  • cetuximab — DRUG

Study Details

A randomized phase II-study to evaluate the safety and efficacy of capecitabine plus irinotecan plus cetuximab compared to capecitabine plus oxaliplatin plus cetuximab in first-line treatment of patients with metastatic colorectal cancer.

Key Dates

Start date
Sep 30, 2004
Status verified
Sep 2004
Completion
Nov 30, 2006

Study Design

Enrollment
92 participants
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

Objective response rate (CR+PR)

Related Studies